Encoded Therapeutics Receives $104 Million to Fuel Development of Precision Gene Therapy

Precision gene therapy company Encoded Therapeutics announced late last month that it has successfully closed its Series C financing round, raising $104 million to be used to develop and bring to market therapeutics aimed at several severe genetic disorders. Specifically, the Bay Area-based biotech startup is planning to use the new capital primarily to fund the development of its marquee program: a precision gene therapy intended to treat Dravet syndrome, a rare form of epilepsy...